{
    "body": "What enzyme is inhibied by Opicapone?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24271646", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23336248", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24148813", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23248072", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24925090"
    ], 
    "ideal_answer": [
        "Opicapone is a novel catechol-O-methyltransferase (COMT) inhibitor to be used as adjunctive therapy in levodopa-treated patients with Parkinson's disease"
    ], 
    "exact_answer": [
        "catechol-O-methyltransferase"
    ], 
    "concepts": [
        "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004791"
    ], 
    "type": "factoid", 
    "id": "56c1d857ef6e394741000033", 
    "snippets": [
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 170, 
            "text": "PURPOSE: Opicapone (OPC) is a novel catechol-O-methyltransferase (COMT) inhibitor to be used as adjunctive therapy in levodopa-treated patients with Parkinson's disease. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24271646", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 162, 
            "text": "Brain and peripheral pharmacokinetics of levodopa in the cynomolgus monkey following administration of opicapone, a third generation nitrocatechol COMT inhibitor.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24148813", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 291, 
            "text": "OBJECTIVE: The present study aimed at evaluating the effect of opicapone, a third generation nitrocatechol catechol-O-methyltransferase (COMT) inhibitor, on the systemic and central bioavailability of 3,4-dihydroxy-l-phenylalanine (levodopa) and related metabolites in the cynomolgus monkey.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24148813", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1431, 
            "offsetInEndSection": 1563, 
            "text": "CONCLUSIONS: Opicapone behaved as long-acting COMT inhibitor that markedly increased systemic and central levodopa bioavailability. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24148813", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 328, 
            "text": "BACKGROUND AND OBJECTIVES: Opicapone is a novel third generation catechol-O-methyltransferase (COMT) inhibitor. The purpose of this study was to compare the levodopa pharmacokinetic profile throughout a day driven by the COMT inhibition either following repeated doses of opicapone or concomitant administration with entacapone.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24925090", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 2232, 
            "offsetInEndSection": 2467, 
            "text": "CONCLUSION: Opicapone, a novel third generation COMT inhibitor, when compared to entacapone, provides a superior response upon the bioavailability of levodopa associated to more pronounced, long-lasting, and sustained COMT inhibition. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24925090", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 241, 
            "text": "Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel catechol-O-methyltransferase inhibitor, in healthy subjects: prediction of slow enzyme-inhibitor complex dissociation of a short-living and very long-acting inhibitor.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23248072", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 67, 
            "text": "Opicapone is a novel catechol-O-methyltransferase (COMT) inhibitor.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23248072", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 84, 
            "text": "Opicapone is a novel third generation catechol-O-methyltransferase (COMT) inhibitor.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24925090", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 95, 
            "offsetInEndSection": 325, 
            "text": "The purpose of this study was to evaluate the tolerability, pharmacokinetics (including the effect of food) and pharmacodynamics (effect on COMT activity) following single oral doses of opicapone in young healthy male volunteers. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23248072", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 208, 
            "text": "AIMS: The aim of this study was to assess the tolerability, pharmacokinetics and inhibitory effect on erythrocyte soluble catechol-O-methyltransferase (S-COMT) activity following repeated doses of opicapone. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23336248", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1180, 
            "offsetInEndSection": 1350, 
            "text": "CONCLUSION: Despite its short elimination half-life, opicapone markedly and sustainably inhibited erythrocyte S-COMT activity making it suitable for a once daily regimen.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23336248", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 2079, 
            "offsetInEndSection": 2171, 
            "text": "Opicapone demonstrated marked and sustained inhibition of erythrocyte soluble COMT activity.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23248072", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1492, 
            "offsetInEndSection": 1597, 
            "text": "The long duration of COMT inhibition by opicapone, however, tended to be independent from the dose taken.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23248072", 
            "endSection": "abstract"
        }
    ]
}